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Abstract
Protein scavenging by macropinocytosis can serve as a source of nutrients for pancreatic cancer 
cells. We provide direct evidence that extracellular protein is a fuel source for pancreatic cancer 
cells in vivo. We demonstrate that albumin-derived peptides and amino acids accumulate in tumors 
in a Kras-driven mouse model of pancreatic ductal adenocarcinoma. In addition, we implement a 
device to deliver large molecules directly into the tumor and observe protein catabolism and 
macropinocytosis by cancer cells within pancreatic tumors. Local release of a macropinocytosis 
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inhibitor leads to a drastic reduction in amino acids levels in tumor tissue arguing that the direct 
uptake and catabolism of extracellular protein is necessary to provide amino acids to pancreatic 
cancer cells in tumors. These data provide evidence for albumin catabolism by tumors and also 
suggest a method for testing therapies that take advantage of the propensity of pancreatic cancer 
cells to scavenge extracellular protein.
INTRODUCTION
Mammalian tissues rely on a variety of nutrients to support physiological function1. Altered 
metabolic processes are involved in the pathogenesis of cancer, but which nutrients support 
inappropriate cancer cell growth within intact tumors is incompletely understood2–4. Amino 
acids, particularly glutamine and serine, have been shown to be essential nutrients for many 
cancer cell lines5,6. Some cancer cells can also obtain key amino acids through catabolism of 
extracellular protein via macropinocytosis to fuel anabolic pathways required for 
growth3,7,8. However, the source of amino acids contributing to cancer cell proliferation 
within intact tumors is less well studied.
Albumin is the most abundant extracellular protein in blood and in tissues, and has been 
previously shown to be internalized into lysosomes of cells in tumors9,10. Hypoalbuminemia 
is observed in many patients with cancer and epidemiological studies suggest that levels of 
serum albumin prior to therapy can be a predictor of survival11,12. Decreased albumin levels 
observed in cancer patients and tumor-bearing animals has been posited to be a result of 
decreased hepatic synthesis or increased degradation by the liver or other organs such as 
skeletal muscle13–16. Direct catabolism of albumin by the tumor itself might also contribute 
to hypoalbuminemia, but the extent to which this occurs in vivo remains controversial due to 
the lack of reliable methods to trace albumin fate.
Macropinocytosis is a conserved, actin-dependent, endocytic process that results in non-
specific bulk internalization of extracellular material, including protein and other 
macromolecules, into the cell7,8,17. Pharmacological and genetic inhibition of 
macropinocytosis can inhibit cell line proliferation and xenograft tumor growth, presenting a 
potential therapeutic target for a subset of tumors7,8. Protein scavenging has been posited 
based on levels of amino acids observed in human pancreatic tumors7, but direct evidence 
that protein is catabolized in a tumor-autonomous manner in vivo is lacking.
We utilize miniaturized plasma exchange to deliver labeled albumin to tissues in live mice 
and demonstrate albumin breakdown contributes to free amino acids in pancreatic tumors in 
vivo. In addition, we deliver albumin directly into the tumor using an implantable 
microdevice, adapted and modified from [18], and directly observe protein catabolism and 
macropinocytosis in situ by cancer cells in pancreatic tumors but not in adjacent non-
cancerous pancreatic tissue. Intratumoral inhibition of macropinocytosis results in a decrease 
in amino acid levels. Taken together, these data suggest pancreatic cancer cells consume 
extracellular protein, including albumin, as a source of amino acids in spontaneously arising 
pancreatic tumors in vivo.
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RESULTS
Isotope-labeled mouse serum albumin [15N]MSA was produced using the yeast Pichia 
pastoris17,19,20 (Supplementary Fig. 1a–c) in order to determine whether albumin could be 
used as a nutrient source by tumors in vivo. Exchanging endogenous albumin in the plasma 
for labeled albumin is necessary to obtain sufficient enrichment of labeled protein over 
reasonable infusion times to trace the fate of labeled albumin in tissues. Because albumin 
has a large volume of distribution in the body and slow turnover (approximately 1–2% total 
per day)11,21, we designed a plasmapheresis approach to exchange endogenous albumin with 
[15N]MSA using a modified perfusion based microfluidic strategy22,23 in mice with and 
without spontaneously arising pancreatic ductal adenocarcinoma (PDAC) (Supplementary 
Fig. 1d, e). PDAC was initiated by pancreas restricted Cre-recombinase (Pdx1-Cre) 
expression in KrasLSL-G12D/+; p53loxP/loxP (KP) mice to induce mutant KrasG12D expression 
and loss of p53.
Following plasmapheresis of control (WT) and KP mice, we achieved an initial plasma 
enrichment of approximately 45% +/− 9.2% labeled albumin (Fig. 1a) with minimal total 
protein loss from the plasma (Supplementary Fig. 2a). Despite slightly lower basal levels of 
protein in KP plasma as compared to WT mice, albumin levels were unchanged even in end-
stage disease in mice with high tumor burden (Supplementary Fig. 2b). We reasoned that if 
albumin is being catabolized, [15N]-labeled amino acids derived from albumin may be 
present in the plasma of these animals after plasma exchange (Fig. 1b). Increased levels of 
labeled alanine, leucine, and phenylalanine were observed in the plasma of tumor-bearing 
KP mice as compared to WT control mice approximately 12 hours after plasma exchange 
indicating the presence of albumin-derived amino acids in the blood and supporting previous 
work suggesting that whole body protein turnover is increased in KP animals with 
pancreatic tumors24 (Fig. 1b). To determine the site(s) of albumin catabolism, we first 
examined labeled albumin peptides and free amino acids in normal pancreas from WT mice 
and PDAC tissue from KP mice. Labeled albumin peptides were increased in tumor relative 
to normal pancreas tissue, suggesting that labeled albumin uptake is increased in tumors 
(Fig. 1c). Next, we examined free amino acids in tumor and normal pancreas following 
plasma-exchange. We observed a significant increase in many labeled free amino acids in 
the tumor relative to the normal pancreas demonstrating that amino acids from the 
breakdown of labeled albumin are enriched in the tumor relative to normal pancreas (Fig. 
1d).
To determine whether albumin-derived amino acids might be generated outside the pancreas 
through catabolism at distant sites, we examined labeled peptides and free amino acids in the 
liver, lung, and muscle of normal (WT) and tumor-bearing (KP) animals (Fig. 1e, f and 
Supplementary Fig. 2c–f). In contrast to the findings in pancreatic tumors compared to 
normal pancreas, we observed no significant increase in albumin peptides in the livers of 
mice with pancreatic cancer relative to mice without pancreatic cancer (Fig. 1e). Some 15N-
labeled free amino acids were increased in the livers of animals with pancreatic cancer (Fig. 
1f) and we also observed elevation in some labeled free amino acids in the lungs of tumor-
bearing animals (Supplementary Fig. 2d). However labeled amino acids were not increased 
in skeletal muscle of mice with PDAC, and neither the lungs nor the skeletal muscle showed 
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an increase in albumin peptides (Supplementary Fig. 2c, e). Together, the findings suggest 
that pancreatic tumors uptake more albumin than normal pancreatic tissues, and amino acids 
from the breakdown of albumin contribute more to the tumor than normal pancreas. The 
presence of labeled amino acids in the liver and other organs (Supplementary Fig. 2c–f) 
leaves open the possibility that the labeling of amino acids in pancreatic tumor tissue results 
from a combination of local albumin catabolism and/or the uptake of free labeled amino 
acids derived from albumin breakdown in non-tumor tissues.
To determine whether tumor-autonomous albumin catabolism is a feature of pancreatic 
tumors, we used an implantable device for delivery of small and large molecules into solid 
tissues (Fig. 2a). The device was adapted from [18] by modifying its diameter and reservoir 
sizes to allow for more effective release of large molecules into the pancreas. This device 
allows direct, controlled delivery of materials into the tumor microenvironment in a defined 
location that can be tracked via microscopy. Macropinocytosis can be visualized by tracking 
the fate of fluorescently labeled high molecular weight dextran (70kDa) a previously 
demonstrated marker of macropinocytosis25. Protein degradation can be assessed by 
employing self-quenched, BODIPY-labeled albumin (DQ-BSA), which becomes fluorescent 
upon enzymatic cleavage in the lysosomes of cells26.
Devices loaded with 1μg of Rh-Dextran and DQ-BSA were implanted into subcutaneous 
xenografts derived from the MIA PaCa-2 (mutant RASV12) and BxPC-3 (WT RAS) human 
PDAC cell lines. These two cells lines have been reported previously to differ in their use of 
macropinocytosis for proliferation in vivo8. The implanted devices allowed local release of 
Rh-Dextran and DQ-BSA adjacent to reservoirs after one day (Fig. 2b). We tracked the fate 
of DQ-BSA and 70kDa Rh-dextran delivered by the micro-devices to investigate whether 
internalization of proteins by macropinocytosis in cells can be observed in these xenograft 
tumors (Fig. 2b, c, d). 24h after device implantation, high levels of dextran uptake and DQ-
BSA fluorescence are observed to ~650μm from the device in MIA PaCa-2 tumor tissue 
(Fig. 2b). Dextran was also released into BxPC-3 tumors, exhibiting a similar gradient of 
intratumoral release as in MIA PaCa-2 tumors (Fig. 2c). Combined local release with EIPA, 
an agent known to inhibit the formation of macropinosomes27, eliminated dextran uptake in 
MIA PaCa-2 tumors (Fig. 2c). We monitored DQ-BSA fluorescence over two days to 
determine whether the observed Dextran diffusion is accompanied by cellular uptake by 
tumor cells and to further examine the kinetics of this degradation. Bright narrow regions of 
fluorescence observed in MIA PaCa-2 tumors indicate local protein degradation that 
appeared approximately 150μm from the device by 24h after device implantation (Fig. 2d). 
At 48h, fluorescent regions appeared at approximately 400μm from the device (Fig. 2d). The 
observed diffusion distances are congruent with previously observed intratumoral release 
studies of several large and small molecules18. In contrast, intratumoral fluorescence from 
DQ-BSA was not observed when identical devices were placed into BxPC-3 xenograft 
tumors (Fig. 2d). These findings argue that local delivery of DQ-BSA allows determination 
of intratumoral albumin catabolism by macropinocytosis.
To determine if we can observe uptake and catabolism of protein in real time, we utilized 
live multiphoton imaging of fluorescence from both DQ-BSA and 70kDa Rh-Dextran 
released from micro-devices in MIA PaCa-2 and BxPC-3 tumors. We observed uptake of 
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dextran and an increase in fluorescent signal from DQ-BSA in cells within xenografted MIA 
PaCa-2 tumors in mice (Fig. 2e). Dextran uptake is observed in the majority of tumor cells 
present within the exposed region at one-hour post-device implantation. Uptake of albumin 
by tumor cells occurs at steady rates, with approximately 2/3 of the cells in an exposed 
region showing internalized Rh-Dextran and DQ-BSA fluorescence within 3 hours of device 
implantation (Fig. 2e), a time consistent with the presence of albumin-derived amino acids 
observed in tumors in mice (Fig. 1). In contrast, the BxPC-3 cell line exhibited Rh-Dextran 
labeling only of cell outlines, and few punctate spots from DQ-BSA were observed 
indicating minimal albumin degradation in these tumors (Fig. 2e). Images from the DQ-BSA 
studies were also used to determine “macropinocytic index”, a metric previously described 
to quantitate macropinocytosis in fixed samples28. By this metric, MIA PaCa-2 cells exhibit 
4-fold higher levels of macropinocytosis relative to BxPC3 cells (Fig. 2f).
To assess macropinocytosis and local protein degradation in KP tumors, microdevices 
containing DQ-BSA were surgically implanted directly into the pancreas of 8-week old KP 
mice harboring autochthonous pancreatic tumors using a biopsy needle. In 8-week old KP 
mice the pancreas appears as a heterogeneous array of tumor and normal tissue24,29 (Fig. 3a 
and Supplementary Fig. 3a). 24h after device delivery, tissue adjacent to device reservoirs 
containing DQ-BSA exhibits fluorescence only when reservoirs were adjacent to tumor 
tissue (Fig. 3a). No fluorescence of DQ-BSA was detected in non-tumor pancreas regions, 
suggesting an absence of albumin degradation at these sites. We next sought to determine the 
kinetics of dextran uptake and DQ-BSA degradation and whether these processes occurred 
in cells with K-rasG12D activation within the pancreas. To distinguish Cre-expressing cells, 
multi-photon live microscopy was utilized in a KP mouse that also harbored a 
tdTomatoLSL/+ allele as a fluorescent marker of Cre-recombinase activity and, therefore, K-
rasG12D activation. Using multi-photon intravital microscopy, we observed a high degree of 
co-localization of fluorescent tdTomato signal and fluorescent DQ-BSA signal (Fig. 3b) and 
an increase in fluorescence due to DQ-BSA degradation was observed over a 90-minute time 
period in tumor cells with tomato fluorescence (Fig. 3c, d). When a microdevice is 
introduced into a KP mouse lacking the tdTomato allele comparable fluorescence from DQ-
BSA is observed in tumor tissue, arguing that the observed DQ-BSA is not the result of 
overlap in the tdTomato and DQ-BSA emission/excitation spectra (Supplementary Fig. 3b). 
Based on DQ-BSA fluorescence, we further observed that the spontaneous KP tumors 
exhibit a level of macropinocytosis comparable to that observed in MIA PaCa-2 xenografts 
(Supplementary Fig. 3c).
One hallmark of pancreatic tumors, including tumors found in KP mice, is a dense stroma 
that is rich in extracellular matrix (ECM)30,31. To determine whether tumor cells can 
internalize ECM-derived proteins, we utilized the microdevice to deliver TRITC-labeled 
fibronectin (440kDa), one of the largest protein components of the extracellular matrix. 
Using intravital microscopy in live mice, we observed clear uptake of fibronectin in tumor 
tissue in KP mice and not in the WT pancreas (Fig. 3e). Taken together, these observations 
suggest that cells in spontaneously arising pancreatic tumors can consume protein in their 
environment.
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Hydroxychloroquine is a lysosomal inhibitor being studied as a potential therapy for 
PDAC32. To determine whether we could inhibit catabolism of DQ-BSA, we delivered 
devices with reservoirs containing DQ-BSA and vehicle or hydroxychloroquine. We 
observed decreased DQ-BSA signal around reservoirs with hydroxychloroquine as 
compared to vehicle reservoirs (Fig. 3f, g), suggesting that the lysosome is involved in the 
catabolism of DQ-BSA in PDAC cancer cells in tumors.
To determine whether inhibiting macropinocytosis with EIPA had an effect on amino acid 
levels in pancreatic tumors, we implanted devices containing EIPA or a vehicle control into 
the pancreas of 7–8 week old KP mice for 24 hours. After tumor harvesting, tissue slices 
adjacent to EIPA or vehicle containing reservoirs were analyzed using matrix-assisted laser 
desorption ionization coupled to imaging mass spectrometry (MALDI-IMS). This enabled 
the simultaneous measurement of EIPA distribution from the device into tumor tissue and 
how relative levels of amino acids might differ spatially within the tissue. We observed no 
change in the relative concentrations of choline, a metabolite that is not expected to be 
affected by EIPA treatment, in tumor tissue regions that were exposed to EIPA 
(Supplementary Fig. 4a). A robust signal for the amino acids glutamate, aspartate, glutamine 
and histidine were also detected in the tissue slices. The relative concentrations of all four 
amino acids were decreased in tissue exposed to EIPA as compared to the adjacent tissue 
that was not exposed to EIPA, and amino acid levels were not changed in tumor tissue 
exposed to vehicle alone (Fig. 4 and Supplementary Fig. 4b). Importantly, the regions of 
tissue analyzed were confirmed to be tumor tissue by H&E stain, with relative 
concentrations of the amino acids detected found to be anti-correlated with regions of tumor 
exposed to EIPA suggesting that exposure to this compound resulted in local amino acid 
depletion (Fig. 4a, b and Supplementary Fig. 4b). In tumor regions adjacent to vehicle 
control reservoirs, the relative concentration of aspartate and glutamate were uniform as 
compared to the rest of the tissue section (Fig. 4c). Using the orientation of device 
placement, we examined the approximate region of vehicle delivery to tumor tissue (400–
500mM), and no differences in aspartate or glutamate levels were observed around the 
predicted region of vehicle delivery (Fig. 4d). Thus, the decreased levels of amino acids in 
the EIPA-exposed regions of the tumor are consistent with the hypothesis that tumors derive 
a meaningful fraction of their amino acids from catabolism of extracellular protein obtained 
by macropinocytosis.
EIPA inhibits macropinocytosis at the concentrations used for these studies7, 8; however, 
EIPA is also an inhibitor of Na+/H+ exchange and may affect amino acid levels by other 
mechanisms. To test this possibility, we determined whether EIPA affected branched-chain 
amino acid (BCAAs) levels under conditions where past work had shown acquisition of 
BCAAs is or is not dependent on macropinocytosis33,34. We found that BCAA levels were 
decreased when pancreatic cancer cells were cultured in media lacking BCAAs, that BCAA 
levels could be rescued by providing cells with excess albumin, and the ability to rescue 
BCAA levels with albumin was inhibited by EIPA while EIPA had no effect on BCAA 
levels otherwise (Supplementary Fig. 4c). We also assessed whether EIPA affected 
intracellular amino acid levels in pancreatic cancer cells in culture where amino acids are 
freely available, and whether EIPA affected uptake of labeled amino acids from the media. 
EIPA had no effect on levels of most amino acids under these conditions (Supplementary 
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Fig. 4d, e), including glutamine, glutamate and aspartate, three of the amino acids found to 
be depleted by EIPA in tumors. These data argue that at the doses use, EIPA has minimal 
effect on the uptake or exchange of free amino acids and strengthens the conclusion that 
macropinocytosis is important to maintain amino acid levels within tumors.
In contrast to previous studies examining albumin synthesis and degradation by different 
organs in tumor bearing animals13,15,35, we provide direct evidence that pancreatic tumors 
catabolize albumin and derive a fraction of amino acids from the breakdown of extracellular 
protein. While these findings remain consistent with breakdown of host tissue proteins as a 
nutrient contributor to pancreatic tumors24, they further suggest that cancer cells in these 
tumors catabolize host-derived proteins in their environment. Hypoalbuminemia was not 
observed in KP mice, suggesting that the quantity of albumin catabolized by tumors is not 
sufficient to directly result in hypoalbuminemia over the time scales this process was studied 
in mice. However, increased turnover of whole body protein stores and albumin 
consumption by tumors may eventually affect circulating albumin levels in patients with 
pancreatic cancers12.
We report two methods to interrogate albumin catabolism that could be extended to other 
solid tumors. Labeling of albumin on specific amino acids could also enable finer mapping 
of the fate of protein-derived amino acids in central carbon metabolism. Using albumin as a 
carrier for chemotherapeutics has been a successful therapeutic strategy in the clinic9,36, 
possibly owing to the propensity of some tumors to use macropinocytosis. Albumin 
conjugation and preferential albumin-uptake can allow for both better solubility and 
improved tumor delivery37. The approaches used here to study local protein catabolism may 
also allow for direct testing of therapeutic hypotheses in an individual tumor, and could be 
used at the time of biopsy to identify patients that might benefit from treatments that take 
advantage of increased protein catabolism by tumors.
METHODS
Animal Statement
All animal studies were approved by the MIT Committee on Animal Care. Mice were 
housed under standard 12-hr light/dark cycles and fed RMH 3000 (Prolab) ad-libitum until 
experiments were conducted. All experimental groups were assigned based on genotype and 
experiments conducted blinded. Plasma exchange experiments were conducted at the same 
time of day. Cohort sizes were based on anticipated results from previous studies in vitro8.
Production of [15N]MSA
The MSA cDNA was cloned from the liver of a wild-type mouse using the following PCR 
primers: (F-GAAGCACACAAGAGTGAGATCGC; R-
TTAGGCTAAGGCGTCTTTGCATCTA). The cDNA was cloned into an expression vector 
containing α-factor and a GAPDH promoter (pGAPZα) for subsequent transformation and 
expression in Pichia pastoris (Invitrogen). P. pastoris expressing MSA was cultured in a 
glucose fed-batch bioreactor (Sartorius) at 30°C for 7 days with [15N]labeled nutrients using 
conditions described previously38. Media containing MSA was separated from the cellular 
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fraction after centrifugation at 15,000xg for 3 hours at 4° C and supernatant containing MSA 
was concentrated using a rotary evaporator. Concentrated supernatant was dialyzed using a 
45,000 Dalton molecular weight cutoff dialysis cassette (Thermo-Fisher) and further purified 
using a Q-Sepharose High Performance anion exchange column (GE). Purified MSA were 
subsequently lyophilized and resuspended in PBS and filtered through 0.45μM filters for use 
in animal experiments. Additional [15N]MSA was acquired from Albumin Biosciences, 
INC.
Microfluidic Plasmapheresis Device
The plasma exchange microfluidic device is based on the concept of cell margination and 
was previously developed for bacterial clearance in a mouse model of sepsis22,23. The device 
is made of polydimethylsiloxane (PDMS) (Sylgard 184, Dow Corning, Midland, MI) and 
consists of 3 channels; each 6 mm long, 20μm × 40μm (W×H) with 3 stages of bifurcation at 
2 mm channel interval. A filter region with an array of square pillars (100μm gap) is added 
upstream of the margination channels to trap large thrombi or cell clusters to ensure smooth 
flow within the device. As blood flows through the margination channel, deformable RBCs 
migrate axially towards the channel center, leaving a layer of plasma next to the channel 
wall which is removed via the smaller side channels. To minimize RBC loss, the side 
channel skimming volume is progressively lower (15%, 10%, 5%) at each bifurcation stage 
with a total volume of ~30%. Therefore, the microdevice is capable of exchanging up to 
~30% of plasma from the incoming blood with labeled albumin, which is infused to the 
filtered blood with a separate syringe pump. During the extracorporeal plasma exchange in 
mice, blood is drawn from an arterial (carotid) catheter using a peristaltic pump (P720, 
Instech Laboratories, Inc., Plymouth Meeting, PA) for ~25 minutes (30μLmin−1) into the 
device which would partially replace the filtered blood with labelled albumin (10μLmin−1) 
prior returning to the animal through a venous (jugular) catheter.
Mouse Pancreatic Cancer Models
For the autochthonous genetically engineered mouse model of pancreatic ductal 
adenocarcinoma (PDAC), tumors were initiated using a pancreas-restricted Pdx1 promoter 
to express Cre-recombinase (Pdx1-Cre) in KrasLSL-G12D/+; p53loxP/loxP animals from a 
mixed 129/Sv and C57Bl6/J background. For imaging studies, mice harboring a 
tdTomatoLSL/+ allele were used to allow visualization of individual cells where Cre was 
expressed. Chronic catheters were implanted in the jugular vein and carotid artery when 
male mice were between 6–8 weeks of age with detectable tumors. For xenograft studies: 
two to four-month old male C57Bl6/J or nu/nu mice were used. Briefly, 2.5×105 established 
cell lines derived from C57Bl6/J KP mice, or 5×105 MIA PaCa2 or BxPC-3 human 
pancreatic cancer cell lines, were injected into the flanks of recipient mice and experiments 
performed when total tumor volume was approximately 1cm3. All human cell lines were 
acquired from ATCC and cultured in 21% oxygen in DMEM containing 10% FBS and 
penicillin/streptomycin.
Metabolite Extraction
Tissues were weighed (wet tissue weight) and homogenized cryogenically (Retsch 
Cryomill). Metabolites were extracted from tissues weighing between 10–40mg in a 
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chloroforom:methanol:water extraction solution at a volume ratio of 400:600:300. Samples 
were vortexed and centrifuged at 10,000×g for 10min to separate aqueous and organic 
layers. Polar metabolites were dried under nitrogen gas and frozen at −80 °C for subsequent 
and analysis by gas-chromatography mass-spectrometry.
Measurement of Labeled Albumin Peptides
Mouse tissue was extracted and homogenized in ice-cold 8 M urea. Proteins were quantified 
using BCA assay (Pierce). Proteins were reduced (10 mM dithiothreitol, 56 °C for 45 min) 
and alkylated (50 mM iodoacetamide, room temperature in the dark for 1 h), then were 
subsequently digested with trypsin (sequencing grade, Promega, Madison, WI) at an 
enzyme/substrate ratio of 1:50 at room temperature overnight in 100 mM ammonium acetate 
pH 8.9. Trypsin activity was quenched by adding formic acid to a final concentration of 5%. 
Peptides were desalted using C18 SpinTips (Protea, Morgantown, WV) then lyophilized and 
stored at −80 °C. After being resuspended in 0.1% formic acid, each sample (1ug of tissue 
or 100 ng of serum) was separated by reverse phase HPLC using an EASY- nLC1000 
(Thermo) over a 75-minute gradient before nanoelectrospray using a QExactive mass 
spectrometer (Thermo). The mass spectrometer was operated in a data-dependent mode. The 
parameters for the full scan MS were: resolution of 70,000 across 350–2000 m/z, AGC 3e6, 
and maximum IT 50 ms. The full MS scan was followed by MS/MS for the top 10 precursor 
ions in each cycle with a NCE of 28 and dynamic exclusion of 30 s. Raw mass spectral data 
files (.raw) were searched using Proteome Discoverer (Thermo) and Mascot version 2.4.1 
(Matrix Science). Mascot search parameters were: 10 ppm mass tolerance for precursor ions; 
0.8 Da for fragment ion mass tolerance; 2 missed cleavages of trypsin; fixed modification 
was carbamidomethylation; variable modification was oxidized methionine. We analyzed the 
following peptides and all possible isotopomers to determine plasma enrichment and 
quantity of labeled albumin present in each tissue: AADKDTcFSTEGPNLVTR (+2), 
AADKDTcFSTEGPNLVTR (+3), APQVSTPTLVEAAR (+2), ENYGELADccTK (+2), 
LVQEVTDFAK (+2), SLHTLFGDK (+2), TcVADESAANcDK (+2) (c = 
carbamidomethylation). Fractional enrichment was determined for each peptide and each 
measurement represents the mean of the 7 peptides. The average fractional enrichment in 
plasma and tissues were normalized to the average fractional plasma enrichments of 
[15N]MSA post plasma-exchange.
Gas-Chromatography Mass-Spectrometry Measurement of Free Amino Acids
Dried tissue metabolites were dissolved in 10uL/10mg of 2% methoxyamine hydrochloride 
in pyridine (Sigma) and held at 37C for 1.5h. Tert-butyldimethylsilyl derivatization was 
initiated by adding 15uL/10mg of N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide 
+ 1% tert-butyldimethylchlorosilane (Sigma) and incubated at 37C for 1hr. GC-MS analysis 
was performed using an Agilent 7890 GC equipped with 30m DB-35MS capillary column 
connected to an Agilent 5975B MS operating under electron impact ionization at 70eV. One 
microliter of sample was injected in splitless mode at 270C, using helium as a carrier gas at 
a flow rate of 1mL min−1. For measurement of polar metabolites, the GC oven temperature 
was held at 100C for 3mins and increased to 300C at 3.5C min−1. The MS source and 
quadrupole were held at 230C and 150C, respectively, and the detector was run in scanning 
mode, recording ion abundance in the range of 100–605m/z. MIDs were determined by 
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integrating the appropriate ion fragments and correct for natural isotope abundance using in 
house algorithms adapted as previously reported (METRAN, Matlab 2013b)8. Labeled 
amino acids are defined as the M+1 (one nitrogen labeled) and M+2 (two nitrogens labeled) 
isotopomers of examined amino acids for 15N labeled studies or M+n (where n= total carbon 
atoms composing each amino acid) for 13C labeled studies.
Albumin Measurements in Plasma
Plasma was collected in EDTA-coated tubes, aliquoted, and frozen at −80°C for further 
analysis. Plasma mouse albumin levels were determined using a mouse albumin ELISA 
assay according to manufacturers’ specification (Abcam #ab108791).
Device to Deliver FITC DQ-BSA, Rh-Dextran, FITC-Dextran, TRITC-Fibronectin, EIPA, and 
Hydroxychloroquine
Microdose drug delivery devices were manufactured as described previously18. In short, 
cylindrical, micro-scale devices with 820μm (diameter) × 4mm (length) were manufactured 
from medical-grade Delrin acetyl resin blocks (DuPont) by micro-machining (CNC 
Micromachining Center, Cameron). Circular reservoirs (2–6 per device) were shaped on the 
outer surface of devices in dimensions of 300μm (diameter) × 250μm (depth). DQ-BSA, 
Dextran, Fibronectin and/or hydroxychloroquine or EIPA (1μg per reservoir) were packed 
into device reservoirs using a tapered, metal needle (Electron Microscopy Sciences). 
Devices were implanted directly into the mouse tumor using a 19-gauge spinal biopsy 
needle (Angiotech) using the retractable needle obturator to push the device into tissue. 
Devices remained in situ for 6–48h. The tumor was then excised and the tissue containing 
the device was snap-frozen. Tissue was sectioned using a standard cryotome and tissue slices 
of 20μm thickness were collected from each reservoir and imaged on an EVOS microscope.
Multi-photon Imaging of DQ-BSA, FITC-Dextran, Rh-Dextran, TRITC-Fibronectin
Intravital multiphoton imaging was performed as described previously39,40 using a 25x 
1.05NA water immersion objective with correction lens. Ninety-minute long time-lapse 
movies were analyzed for measuring and quantifying fluorescence intensity and cell 
characteristics in 3D and through time using NIH ImageJ41. Data were pooled from at least 
3 mice per tumor group, with 4–8 fields imaged per mouse. Macropinocytic index was 
determined as previously described for xenograft tumors 28.
MALDI Imaging experiments
Samples were cryosectioned at 20 μm, thaw-mounted on glass slides, and serial sections 
analyzed. The orientation of specimens was shifted for serial sections analyzed in positive 
versus negative ion mode, with device location used to orient the sample in each serial 
section. Slides were then coated with HCCA (7 mg/mL, 50% methanol, 0.1% TFA) or 9-
aminoacridine (10 mg/mL, 70% ethanol, 0.1% TFA) using a TM sprayer (HTX 
Technologies, Carrboro, NC, USA). Serial sections were prepared for imaging analysis in 
both positive and negative ion modes on a 7T solariX-XR FTMS (Bruker, Billerica, MA, 
USA) equipped with dual ESI/MALDI source, SmartBeam II 2 kHz Nd:YAG (355 nm) 
laser, and paracell. Samples were analyzed with a raster width of 125 μm in positive ion 
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mode and 100 um in negative ion mode in the mass range of 80 – 2000 m/z at 2MW 
acquisition size. Images contained between 7200 and 10500 pixels. Data was visualized and 
co-registration of H&E images performed using FlexImaging 4.1. Compound identifications 
were made on the basis of accurate mass (<1ppm) and isotopic peak matching.
Cell Culture
Cell lines from murine KP pancreatic tumors were established by standard protocols24. Cells 
were cultured in complete DMEM with 10% fetal bovine serum and 5% penicillin/
streptomycin. For BCAA deprivation, DMEM with 5% dialyzed serum with or without 
BCAAs (leucine, valine, and isoleucine) was used in the presence or absence of 3% albumin 
and in the presence or absence of 20μM EIPA. Where indicated, 2mg/mL of a fully 
labeled 15N or 13C labeled amino acid mixture (Cambridge Isotopes Laboratories) was 
included for 6 hours prior to metabolite extraction.
Statistical Analysis
Two-tailed unpaired Student’s T-test was performed for all experiments and data were 
normally distributed for all analyses conducted. Variances were not statistically different in 
any of the data. Results for independent experiments are presented as mean ± SD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Albumin-derived amino acids are found in pancreatic tumors
a. Representative albumin enrichment in the plasma of WT and KP mice following plasma 
exchange of [15N]-labeled mouse serum albumin ([15N]MSA) for endogenous albumin as 
assessed by analysis of labeled albumin peptides. The %[15N]MSA shown was obtained by 
analysis of the albumin peptide LVQEVTDFAK in plasma by LC-MS/MS over time during 
and after plasma exchange (n = 5 per genotype). The time indicated by the double dagger 
corresponds to the 30-minute period of plasma exchange.
b. Labeled amino acids in the plasma of WT and KP mice following plasma exchange of 
[15N]-labeled MSA for endogenous MSA. Plasma was sampled at the time of tissue 
collection (~12 hours post-exchange). The presence of [15N]-labeled amino acids was 
determined by GC-MS, (n = 5 per genotype).
c. Following plasma exchange of [15N]-labeled MSA for endogenous MSA in WT and KP 
mice, the presence of [15N]MSA in tissue was determined by analysis of multiple labeled 
peptides from normal pancreas (WT) or pancreatic tumors (KP) by LC-MS/MS, (n = 5 per 
genotype).
Davidson et al. Page 14
Nat Med. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
d. The presence of labeled amino acids in the pancreas (WT) or tumor (KP) from WT and 
KP mice respectively following plasma exchange of [15N]-labeled MSA for endogenous 
MSA. Tissues were collected ~12 hours post-exchange and labeled amino acids determined 
by GC-MS (n = 5 per genotype).
e. Following plasma exchange of [15N]-labeled MSA for endogenous MSA in WT and KP 
mice, the presence of [15N]MSA in tissue was determined by analysis of multiple labeled 
peptides from livers of animals with pancreatic tumors (KP) or without pancreatic tumors 
(WT) by LC-MS/MS, (n = 5 per genotype).
f. The presence of labeled amino acids in the livers of WT or KP mice ~12 hours following 
plasma exchange of [15N]-labeled albumin for endogenous albumin. Labeled amino acids 
were determined by GC-MS.
For all panels, (Ala = alanine; Asp = aspartate; Cys = cysteine; Gln = glutamine; Glu = 
glutamate; Gly = glycine; Ile = isoleucine; Leu = leucine; Lys = lysine; Met = methionine; 
Phe = phenylalanine; Ser = serine; Thr = threonine; Val = valine), significance differences 
are noted as P * < 0.05; ** < 0.01; ***<0.001; n.s. difference not significant, by unpaired t-
test.
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Figure 2. Direct assessment of macropinocytosis and albumin catabolism in tumors
a. Schematic depicting device implanted directly into the tumor to release specified contents 
from reservoirs into distinct tissue regions. Radially outward diffusion of compounds from 
reservoirs is shown in 3-dimensional (left) and cross-sectional views (right). The orientation 
of the schematic on the right matches the orientation of device placement relative to tissue in 
panels b, c, and d.
b. Combined delivery of 70 kDa rhodamine-dextran (Rh-Dextran) and self-quenched, 
BODIPY-labeled bovine serine albumin (DQ-BSA). Both compounds are released from a 
single reservoir in MIA PaCa-2 tumors. Radial transport of compound is ~150 μm from the 
device into tissue after a 24h incubation period. Scale bar, 200 μm. (images are 
representative of n = 6 from mice per cell line per condition with triplicate reservoirs).
c. Delivery of 70 kDa Rh-Dextran from the device into MIA PaCa-2 and BxPC-3 tumor 
tissue at 48h. Unlike MIA PaCa-2 tumors, BxPC-3 tumors have been shown previously not 
to engage in macropinocytosis8. Tissue penetration up to ~550 μm is observed in each 
tumor. Co-delivery of 70kDa Rh-Dextran with the macropinocytosis inhibitor EIPA leads to 
reduced Rh-Dextran uptake in MIA PaCa-2 tumor tissue as shown. Scale bar, 150 μm. 
(images are representative of n = 6 from two mice per cell line per condition with triplicate 
reservoirs).
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d. Comparison of albumin breakdown in MIA PaCa-2 and BxPC-3 tumor sections. Devices 
containing DQ-BSA were implanted into MIA PaCa-2 and BxPC-3 tumors as indicated. 
Degradation of BSA, indicated by fluorescence signal from DQ-BSA, increases over time in 
MIA PaCa-2 tumors a depth of 200μm from the device after 1 day, and up to 350μm from 
the device after 2 days. Scale bar, 200 μm. (images are representative of n = 6 from two mice 
per cell line per condition with triplicate reservoirs).
e. Examination of albumin and dextran uptake in MIA PaCa-2 and BxPC-3 tumors. 
Multiphoton images of live tumors implanted with devices containing 70kDa Rh-Dextran 
and DQ-BSA. Fluorescence from DQ-BSA is observed in individual cells in MIA PaCa-2 
tumors by 4h after device implantation, and high concordance is observed between cells that 
display Rh-Dextran uptake and DQ-BSA fluorescence. Scale bar, 20 μm. (images are 
representative of n = 2 mice per cell line per condition with duplicate reservoirs).
f. Quantification of relative macropinocytic index in MIA PaCa-2 and BxPC-3 xenograft 
tumors based on DQ-BSA fluorescence. Macropinocytic index is a ratio of the total area of 
all macropinosomes in a field of designated area (n=5 distinct fields per cell line). For all 
panels, white arrows indicate direction of delivery of DQ-BSA, Rh-Dextran, or EIPA. (data 
from n = 2 mice per cell line per condition with duplicate reservoirs used to calculate 
macropinocytic index). Significance values indicated as P ** < 0.01, by unpaired t-test.
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Figure 3. Albumin catabolism and fibronectin internalization in autochthonous KrasG12D-driven 
pancreatic tumors catabolize albumin and internalize fibronectin
a. Differential albumin breakdown in tumor compared to normal pancreatic tissue. Devices 
containing self-quenched, BODIPY-labeled bovine serine albumin (DQ-BSA) were 
implanted directly into the pancreas of KP mice with pancreatic tumors. Tissue sections 
visualized by bright-field (left) and fluorescence (right) microscopy are shown. Arrows 
indicate reservoir position that corresponds to the site of DQ-BSA delivery. DQ-BSA 
fluorescence is observed only in areas where the device contacts tumor tissue (top), and not 
when the device is adjacent to non-malignant pancreatic tissue (bottom). (images are 
representative of n = 2 mice per cell line per condition with triplicate reservoirs).
b. Cellular fate of albumin catabolism. Multiphoton microscopy images of pancreatic tumors 
in live KP mice that also harbor a tdTomatoLSL allele (KPT) to mark cancer cells with red 
fluorescence. Images were obtained 4h post device implantation to deliver DQ-BSA. Green 
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fluorescence corresponding to catabolism of DQ-BSA localizes with tumor cells marked by 
red fluorescence. Low (top) and high power (bottom) images are shown. Scale bar, 20 μm 
for both low and high power images. (images are representative of n = 4 mice per cell line 
per condition with duplicate reservoirs).
c. Multiphoton images of pancreatic tumors in live KPT mice showing increasing 
fluorescence from DQ-BSA over time. Red fluorescence marking tumor cells (top) and 
green fluorescence from DQ-BSA (bottom) are shown at 10- and 90-minutes post device 
implantation. Scale bar, 50 μm. (images are representative of n = 2 mice per genotype per 
condition with duplicate reservoirs).
d. Quantification of DQ-BSA fluorescence from the experiment in (C) reveals greater than 
3-fold increase in fluorescence from 10- to 90-minutes. tdTomato fluorescence is also shown 
and changes minimally over the same 90-minute period. (n = 2 mice per genotype per 
condition with duplicate reservoirs).
e. Multiphoton images of normal pancreas (WT) and pancreatic tumors (KP) in live mice. 
Second harmonic generation is used to detect fibrillar collagen and displayed to demonstrate 
background auto-fluorescence in the TRITC channel. Images were obtained 30min post 
device implantation to deliver TRITC-Fibronectin (yellow). Cellularity of internalized 
TRITC-fibronectin was visualized and observed only in KP mice. White dashed outline 
indicates area of magnification to demonstrate cellular distribution of TRITC-fibronectin. 
Scale bar, 20μM. (Images are representative of n = 2 mice per genotype per condition with 
duplicate reservoirs).
f. Devices containing self-quenched, BODIPY-labeled bovine serine albumin (DQ-BSA) 
with vehicle or the lysosomal inhibitor hydroxychloroquine (HCQ) were implanted directly 
into the pancreas of KP mice with pancreatic tumors. Tissue sections visualized by bright-
field (left) and fluorescence (right) microscopy are shown. White arrows indicate reservoir 
position that corresponds to the site of DQ-BSA delivery. A strong decrease in DQ-BSA is 
observed in the presence of HCQ (images are representative of n = 5 distinct regions of 
tumor per condition).
g. Quantification of fluorescent intensity of DQ-BSA in the presence and absence of HCQ (n 
= 5 distinct regions of tumor per condition). Significance values indicated as P ** < 0.01, by 
unpaired t-test.
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Figure 4. Local depletion of amino acids following inhibition of macropinocytosis in KrasG12D-
driven pancreatic tumors in vivo
a. Devices containing EIPA were implanted directly into pancreatic tumors of KP mice. 24 
hours after device implantation, serial sections from the tumor were analyzed by matrix 
assisted laser desorption ionization coupled to imaging mass-spectrometry (MALDI-IMS). 
Positive ion mode was used to detect the macropinocytosis inhibitor, EIPA (top panels; EIPA 
diffused approximately 400–500μM). Negative ion mode used to detect the amino acids 
aspartate and glutamate (middle and bottom panels respectively). A scale bar representing 
the intensity range of ions detected for each image is included in the lower right of each 
panel and the length of this bar corresponds to 1mm. The left panels (MS) show the mass 
spectrometry signal only, the center panels (BF, MS) show an overlay of the mass 
spectrometry signal with a bright field image of an adjacent tissue section, and the right 
panels (H&E, MS) show an overlay of the mass spectrometry signal and an H&E stain of an 
adjacent tissue section. Schematic demonstrating device placement is included in the upper 
right as a white circle with an arrow indicating direction of EIPA release. A blue line 
indicates the extent of the EIPA signal in the H&E, MS images. Images are representative of 
n = 2 KP mice with triplicate reservoirs.
b. Qualitative signal for EIPA (blue) and signal from the amino acids aspartate (top) and 
glutamate (bottom) (red) are shown as separate and overlaid images as indicated. Also 
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shown is an outline (blue line) of the extent of EIPA signal overlaid on the aspartate and 
glutamate signal as indicated. White scale bar corresponds to 1mm.
c. Devices containing vehicle control (polyethylene glycol) were implanted directly into 
pancreatic tumors of KP mice. 24 hours after device implantation, serial sections from the 
tumor were analyzed by matrix-assisted laser desorption ionization coupled to imaging 
mass-spectrometry (MALDI-IMS). Positive ion mode was used to demonstrate the absence 
of the macropinocytosis inhibitor, EIPA (top panels; No EIPA observed, vehicle). Negative 
ion mode used to detect the amino acids aspartate and glutamate (middle and bottom panels 
respectively). A scale bar representing the intensity range of ions detected for each image is 
included in the lower right of each panel and the length of this bar corresponds to 1mm. The 
left panels (MS) show the mass spectrometry signal only, the center panels (BF, MS) show 
an overlay of the mass spectrometry signal with a bright field image of an adjacent tissue 
section, and the right panels (H&E, MS) show an overlay of the mass spectrometry signal 
and an H&E stain of an adjacent tissue section. Schematic demonstrating device placement 
is included in the upper right as a white circle with an arrow indicating direction of vehicle 
release. A blue dashed line indicates the approximate extent of diffusion based on diffusion 
of EIPA in A. Images are representative of n = 2 KP mice with triplicate reservoirs.
d. Qualitative signal for EIPA (blue) and signal from the amino acids aspartate (top) and 
glutamate (bottom) (red) are shown as separate and overlaid images as indicated. Also 
shown is an outline (blue dashed line) of the expected extent of EIPA diffusion if it were 
included in the reservoir. White scale bar corresponds to 1mm.
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